Skip to main content
SpringerLink
Log in

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies

  • REVIEW
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

CD20 has proven to be an excellent target for the treatment of B-cell lymphoma, first for the chimeric monoclonal antibody rituximab (Rituxan™), and more recently for the radiolabelled antibodies Y-90 ibritumomab tiuxetan (Zevalin™) and I-131 tositumomab (Bexxar™). Radiation therapy effects are due to beta emissions with path lengths of 1–5 mm; gamma radiation emitted by I-131 is the only radiation safety issue for either product. Dose-limiting toxicity for both radiolabelled antibodies is reversible bone marrow suppression. They produce response rates of 70%–90% in low-grade and follicular lymphoma and 40%–50% in transformed low-grade or intermediate-grade lymphomas. Both products produce higher response rates than related unlabelled antibodies, and both are highly active in patients who are relatively resistant to rituximab-based therapy. Median duration of response to a single course of treatment is about 1 year with complete remission rates that last 2 years or longer in about 25% of patients. Clinical trials suggest that anti- CD20 radioimmunotherapy is superior to total body irradiation in patients undergoing stem cell supported therapy for B-cell lymphoma, and that it is a safe and efficacious modality when used as consolidation therapy following chemotherapy. Among cytotoxic treatment options, current evidence suggests that one course of anti-CD20 radioimmunotherapy is as efficacious as six to eight cycles of combination chemotherapy. A major question that persists is how effective these agents are in the setting of rituximab- refractory lymphoma. These products have been underutilised because of the complexity of treatment coordination and concerns regarding reimbursement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dillman RO (2001) Monoclonal antibody therapy for lymphoma. Cancer Practice 9:71–80

    Article  PubMed  CAS  Google Scholar 

  2. Dillman RO (1997) Magic bullets at last! Finally — approval of a monoclonal antibody for the treatment of cancer!!! Cancer Biother Radiopharm 12:223–225

    PubMed  CAS  Google Scholar 

  3. Dillman RO (2003) Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Semin Oncol 30:434–447

    Article  PubMed  CAS  Google Scholar 

  4. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dellaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833

    PubMed  CAS  Google Scholar 

  5. Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, White WL, Chalchal HI, Flynn PJ, Fitch TR, Welker DA (2005) Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23:1103–1108

    Article  PubMed  CAS  Google Scholar 

  6. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haioun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boue F, Taillan B, Lederlin P, Najman A, Thieblemont C, Montestruc F, Mathieu-Boue A, Benzohra A, Solal-Celigny P (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101–106

    Article  PubMed  CAS  Google Scholar 

  7. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA (2005) Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma — a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23:1088–1095

    Article  PubMed  CAS  Google Scholar 

  8. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, Fey MF, Betticher DC, Martinelli G, Peccatori F, Hess U, Zucca E, Stupp R, Kovacsovics T, Helg C, Lohri A, Bargetzi M, Vorobiof D, Cerny T (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416–4423

    Article  PubMed  CAS  Google Scholar 

  9. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22:4711–4716

    Article  PubMed  CAS  Google Scholar 

  10. Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH (2005) Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 23:694–704

    Article  PubMed  CAS  Google Scholar 

  11. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI (2005) Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 46:1569–1573

    Article  PubMed  CAS  Google Scholar 

  12. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the RCHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117–4126

    Article  PubMed  CAS  Google Scholar 

  13. Habermann TM, Weller E, Morrison VA, Cassileth PA, Cohn J, Dahhil S, Gascoyne RD, Woda B, Fisher B, Peterson BA, Horning SJ (2004) Rituxima-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma: an update. Blood 104:40a [Abstract 127]

    Article  CAS  Google Scholar 

  14. Pfreundschuh M, Truemper L, Gill D, Osterborg A, Pettengell R, Trneny M, Imrie K, Walewski J, Zinzani P-L, Loeffler M (2004) First analysis of the completed Mabthera international (MInT) trial in young patients with low-risk diffuse large B-cell lymphoma: addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=0 and no bulky disease. Blood 104:48a [Abstract 157]

    Google Scholar 

  15. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417–1423

    Article  PubMed  CAS  Google Scholar 

  16. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Bock HP, Wandt H, Unterhalt M, Hiddemann W (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064–3071

    Article  PubMed  CAS  Google Scholar 

  17. Sehn LH, Donaldson J, Chanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027–5033

    Article  PubMed  CAS  Google Scholar 

  18. Fisher RI, Leblanc M, Press OW, Maloney DG, Unger JM, Miller TP (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23:8447–8452

    Article  PubMed  CAS  Google Scholar 

  19. Dillman RO, Chico SD (2005) Improved survival of lymphoma patients after introduction of rituximab. Blood 106:242b [Abstract 4650]

    Google Scholar 

  20. Dillman RO (2002) Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 20:3545–3557

    Article  PubMed  CAS  Google Scholar 

  21. Cheson BD (2003) Radioimmunotherapy of non-Hodgkin’s lymphoma. Blood 101:391–398

    Article  PubMed  CAS  Google Scholar 

  22. Siegel JA (1998) Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy. J Nucl Med 39[Suppl 8]:28s–33s

    PubMed  CAS  Google Scholar 

  23. Gates VL, Carey JE, Siegel JA, Kaminski MS, Wahl RL (1998) Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy. J Nucl Med 39:1230–1236

    PubMed  CAS  Google Scholar 

  24. Rutar FJ, Augustine SC, Kaminski MS, Wahl RL, Siegel JA, Colcher D (2001) Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin’s lymphoma based on radiation doses to family members. Clin Lymphoma 2:164–172

    Article  PubMed  CAS  Google Scholar 

  25. Wagner HN Jr, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, Lamonica DM, Conti PS (2002) Administration guidelines for radioimmunotherapy of non-Hodgkin’s lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 43:267–272

    PubMed  CAS  Google Scholar 

  26. Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DH, Berlfein JR, Ding E, Grillo-Lopez AJ (2000) Phase I/II 90-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med 27:766–777

    Article  PubMed  CAS  Google Scholar 

  27. Erwin WD, Spies SM, Kelly ME, Rao P, Eckersberg-Rhodes TE, Nannapaneni M, Groch MW (2001) Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin’s B-cell lymphoma. Nucl Med Commun 22:247–255

    Article  PubMed  CAS  Google Scholar 

  28. Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA (2003) Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from 4 clinical trials. J Nucl Med 44:465–474

    PubMed  CAS  Google Scholar 

  29. Wiseman G, Conti P, Vo K, Schilder RJ, Foster P, Gordon LI, Emmanouilides C, Silverman D, Witzig TE (2004) Evaluation of baseline body-weight dosing of yttrium 90 ibritumomab tiuxetan (Zevalin) in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Blood 104:721a [Abstract 2634]

    Google Scholar 

  30. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL (1996) Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974–1981

    PubMed  CAS  Google Scholar 

  31. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-Lopez AJ (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma. J Clin Oncol 17:3793–3803

    PubMed  CAS  Google Scholar 

  32. Dillman RO (1999) Infusion reactions associated with the infusion of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 18:465–471

    Article  PubMed  CAS  Google Scholar 

  33. Vose JM, Zelenetz AD, Rohatiner A, Knox S, Stagg R, Kroll S, Tidmarsh G, Kaminski MS (1999) Iodine I 131 tositumomab for patients with follicular non-Hodgkin’s lymphoma: overall clinical trial experience by histology. Blood 94:89a [Abstract 387]

    Google Scholar 

  34. Davies AJ, Rohatiner AZ, Howell S, Britton KE, Owens SE, Micallef IN, Deakin DP, Carrington BM, Lawrance JA, Vinnicombe S, Mather SJ, Clayton J, Foley R, Jan H, Kroll S, Harris M, Amess J, Norton AJ, Lister TA, Radford JA (2004) Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 22:1469–1479

    Article  PubMed  CAS  Google Scholar 

  35. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20:2453–2463

    Article  PubMed  CAS  Google Scholar 

  36. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM (2001) Pivotal study of Iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell lymphomas. J Clin Oncol 19:3918–3928

    PubMed  CAS  Google Scholar 

  37. Zelenetz AD, Saleh M, Vose J, Younes A, Kaminski MS (2002) Transformed low grade lymphoma attain durable response following outpatient radioimmunotherapy with tositumoab and iodine I 131 tostitumomab (Bexxar®). Blood 100:357a [Abstract 1384]

    Google Scholar 

  38. Bartlett NL, Witzig TE, Gordon L, Beck T, Fehrenbacher L, Kornmehl E, Levy R, Terry LN, Murray JL, Raubitschek A, Vo K, White CA (2002) 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin’s lymphoma patients. Proc Am Soc Clin Oncol 21:14a [Abstract 51] 10

    Google Scholar 

  39. Leonard JP, Frenette G, Dillman RO, Gregory SA (2001) Interim safety and efficacy results of Bexxar™ in a large multicenter expanded access study. Blood 98:133a [Abstract 559]

    Google Scholar 

  40. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SJ (2004) The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 10:7792–7798

    Article  PubMed  CAS  Google Scholar 

  41. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximabrefractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 20:3262–3269

    Article  PubMed  CAS  Google Scholar 

  42. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23:712–719

    Article  PubMed  CAS  Google Scholar 

  43. Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C, Pohlman B, Bartlett N, Wiseman G, Darif M, White C (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5:98–101

    Article  PubMed  CAS  Google Scholar 

  44. Wiseman GA, Witzig TE (2005) Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin’s lymphoma. Cancer Biother Radiopharm 20:185–188

    Article  PubMed  CAS  Google Scholar 

  45. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, Leonard JP, Kroll S, Goldsmith SJ, Coleman M (2005) Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas. J Clin Oncol 23:7565–7573

    Article  PubMed  CAS  Google Scholar 

  46. Flinn IW, Witzig TE, White CA, Gordon L, Emmanoulides C, Cripe LD, Saleh M, Czuczman MS, Spies S, Silverman DH, Burt RW (2001) The Zevalin radioimmunotherapy regimen is active in heavily pretreated, bulky, rituximab refractory NHL. Proc Am Soc Clin Oncol 20:286a [Abstract 1141]

    Google Scholar 

  47. Kaminski MS, Leonard JP, Zelenetz AD, Vose JM (2002) Bexxar therapy (tositumomab and iodine I 131 tositumomab) has high response rates in the treatment of bulky low grade, relapsed or refractory non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 21:5a [Abstract 17]

    Google Scholar 

  48. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441–449

    Article  PubMed  CAS  Google Scholar 

  49. Sweetenham JW, Dicke K, Acaroli J, Kogel K, Rana TM, Rice LL (2004) Efficacy and safety of yttrium 90 ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma. Blood 104:720a [Abstract 2633]

    Google Scholar 

  50. Emmanouilides CE, Witzig TE, Molina A, Gordon LI Multani P, Wiseman GA, Darif M, Murray JL, Lister J, White CA (2003) Improved safety and efficacy of yttrium-90 ibrituomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular, and transformed B-cell non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 22:595 [Abstract 2392]

    Google Scholar 

  51. Gregory SA, Leonard JP, Vose JM, Zelenetz AD, Horning SJ, Knox SJ, Lister TA, Radford JA, Press OW, Kaminski MS (2005) Superior outcomes associated with earlier use: experience with tositumomab and iodine I 131 tositumomab in 1,177 patients with low-grade, follicular, and transformed non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 23:585s [Abstract 6561]

    Google Scholar 

  52. Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, Wahl RL (2005) Re-treatment with I-131 tositumomab in patients with non-Hodgkin’s lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol 23:7985–7993

    Article  PubMed  CAS  Google Scholar 

  53. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE (2002) Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin’s lymphoma. J Clin Oncol 20:3885–3890

    Article  PubMed  CAS  Google Scholar 

  54. Schilder RJ, Witzig T, Gordon L, Emmanouilides CE, Bartlett NL, Flinn IW, Ugoretz R, Ding E, Czuczman MS, White CA (2002) 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma. Proc Am Soc Clin Oncol 21:267a [Abstract 1064]

    Google Scholar 

  55. Saleh F, Saleh M, Witzig T, Gordo L, Emmanouilides CE, Raubitschek A, Wiseman G, Vo K, Landin R, White CA (2002) Rituximab administration subsequent to ibritumomab tiuxetan (Zevalin) radioimmunotherapy. Proc Am Soc Clin Oncol 21:8a [Abstract 30]

    Google Scholar 

  56. Dosik A, Hack S, Navarro M, Kostakoglu L, Coleman M, Fiore JM, Scarano D, Kroll S, Vallabhajosula S, Goldsmith SJ, Leonard JP (2002) Cytotoxic chemotherapy for non-Hodgkin’s lymphoma can be safely administered following relapse from iodine 131 tositumomab (Bexxar). Proc Am Soc Clin Oncol 21:267a [Abstract 1065]

    Google Scholar 

  57. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI (2003) Aphase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: Southwest Oncology Group Protocol S9911. Blood 102:1606–1612

    Article  PubMed  CAS  Google Scholar 

  58. Link B, Kaminski MS, Coleman M, Leonard JP (2004) Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 23:560a [Abstract 6520]

    Google Scholar 

  59. Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, Schuster MW, Niesvizky R, Muss D, Fiore J, Kroll S, Tidmarsh G, Vallabhajosula S, Goldsmith SJ (2005) Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 23:5696–5704

    Article  PubMed  CAS  Google Scholar 

  60. Shipley DL, Spigel DR, Carrell DL, Dannaher C, Greco FA, Hainsworth JD (2004) Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 23:560a [Abstract 6519]

    Google Scholar 

  61. Jacobs SA, Vidnovic N, Joyce J, McCook B, Torok F, Avril N (2005) Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res 11:7146s–7150s

    Article  PubMed  CAS  Google Scholar 

  62. Vose JM, Bierman PJ, Lynch JC, Bociek GR, Multani PS, Armitage JO (2003) Phase I clinical trial of Zevalin (Y-90 ibritumomab) in patients with B-cell non-Hodgkin’s lymphoma with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation. Blood 102:30a [Abstract 92]

    Google Scholar 

  63. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219–1224

    Article  PubMed  CAS  Google Scholar 

  64. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T (1995) Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346: 336–340

    Article  PubMed  CAS  Google Scholar 

  65. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, Gooley TA, Bernstein ID, Press OW (1998) Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16:3270–3278

    PubMed  CAS  Google Scholar 

  66. Rajendran JG, Fisher DR, Gopal AK, Durack LD, Press OW, Eary JF (2004) High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin’s lymphoma: adjusting radiation absorbed dose to actual organ volumes. J Nucl Med 45:1059–1064

    PubMed  CAS  Google Scholar 

  67. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Matthews DC, Appelbaum FR, Bernstein ID (2000) A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934–2942

    PubMed  CAS  Google Scholar 

  68. Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, Bush SA, Durack LD, Golden J, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW (2003) High-dose radioimmunotherapy versus conventional highdose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 102:2351–2357

    Article  PubMed  CAS  Google Scholar 

  69. Winter JN (2004) Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin’s lymphoma. Clin Lymphoma 5[Suppl 1]:S22–S26

    Article  PubMed  CAS  Google Scholar 

  70. Nademanee A, Forman SJ, Molina A, Kogut N, Fung HC, Yamauchi D, Anderson A-L, Smith D, Liu AN, Raubitschek A (2004) High-dose radioimmunotherapy with yttrium 90 ibritumomab tiuxetan with high-dose etoposide and cyclophosphamide followed by autologous hematopoietic cell transplant for poor-risk or relapsed B-cell non-Hodgkin’s lymphoma: update of a phase I/II trial. Proc Am Soc Clin Oncol 23:557 [Abstract 6504]

    Google Scholar 

  71. Joyce J, Schuster MW, McCook B, Torok F, Avril N, Vidnovic N, Jacobs SA (2005) Experience with yttrium 90 ibritumomab tiuxetan after autologous stem cell transplant in patients with non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 23:602s [Abstract 6669]

    Google Scholar 

  72. Morschhauser F, Huglo D, Martinelli G, Paganelli G, Zinzani PL, Hadjiyiannakis D, Liberati A, Illidge T, Milpied N, Stein H, Kalmus J, Morel P, Reimann U, Marcus R (2004) Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial. Blood 104:41a [Abstract 130]

    Google Scholar 

  73. Zelenetz AD, Donnelly G, Halaas J, Sgouros G, Humm J, Popplewell L, Reyes S, Maignan K, Campbell C, Moskowitz CH, Nimer SD, Pandit-Taskar N, Divgi C (2003) Initial treatment of mantle cell lymphoma with sequential radioimmunotherapy with tositumomab/Iodine I131 I-tositumomab followed by CHOP chemotherapy results in a high complete remission rate. Blood 102:406a [Abstract 1477]

    Google Scholar 

  74. Oki Y, Pro B, Delpassand E, Ballaster V, McLaughlin P, Romaguera J, Wang M, Hagemeister FB, Younes A (2004) A phase II study of Ytrrium 90 ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma. Blood 104:720a [Abstract 2632]

    Google Scholar 

  75. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS (2003) Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma. J Clin Oncol 21:1263–1270

    Article  PubMed  CAS  Google Scholar 

  76. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin’s lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336–4342

    Article  PubMed  CAS  Google Scholar 

  77. Schilder R, Molina A, Bartlett N, Witzig T, Gordon L, Murray J, Spies S, Wang H, Wiseman G, White C (2004) Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin’s lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 19:478–481

    PubMed  CAS  Google Scholar 

  78. Czuczman M, Witzig TE, Gaston I, Skikne BS, Dimitrov G, Gordon LI, Emmanouilides C, White CA (2002) Zevalin™ radioimmunotherapy is not associated with an increased incidence of secondary myelodysplastic syndrome or acute leukemia. Blood 100:357a [Abstract 1386]

    Google Scholar 

  79. Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, Horning S, Press OW, Radford JA, Kroll SM, Capizzi RL (2005) Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105:4576–4582

    Article  PubMed  CAS  Google Scholar 

  80. Holm LE, Hall P, Wiklund K, Lundell G, Berg G, Bjelkengren G, Cederquist E, Ericsson UB, Hallquist A, Larsson LG, Lidberg M, Lindberg S, Tennvall J, Wicklund H, Boice Jr JD (1991) Cancer risk after idoine-131 therapy for hyperthyroidism. J Natl Cancer Inst 83:1072–1077

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical and Scientific Director, Hoag Cancer Center, Newport Beach, CA 92658, USA

    R. O. Dillman

Authors
  1. R. O. Dillman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. O. Dillman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dillman, R.O. Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies. Clin. Exper.Med. 6, 1 (2006). https://doi.org/10.1007/s10238-006-0087-6

Download citation

  • Received:

  • Accepted:

  • DOI: https://doi.org/10.1007/s10238-006-0087-6

Key words

Search

Navigation